MTP - Midatech Pharma Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1168
+0.0041 (+3.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.1127
Open0.1150
Bid0.1033 x 2200
Ask0.1200 x 800
Day's Range0.1131 - 0.1168
52 Week Range0.1030 - 1.8000
Volume206,724
Avg. Volume450,421
Market Cap3.167M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.8480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters18 days ago

    BRIEF-China Medical System Holdings Unit Signs Agreement With Midatech Pharma PLC

    Jan 29 (Reuters) - China Medical System Holdings Ltd : * UNIT SIGNED A LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENT WITH MIDATECH PHARMA PLC * CHINA MEDICAL SYSTEM HOLDINGS - UNIT SIGNED A LICENSE, ...

  • Simply Wall St.2 months ago

    Here’s What Münchener Tierpark Hellabrunn AG’s (MUN:MTP) P/E Is Telling Us

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Münchener Tierpark Hellabrunn AG's (MUN:MTP) P/E ratio and reflect Read More...

  • Simply Wall St.4 months ago

    Why Münchener Tierpark Hellabrunn AG (MUN:MTP) Delivered An Inferior ROE Compared To The Industry

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • Zacks Small Cap Research4 months ago

    MTP: Converting to R&D Focused Company Through Divestiture of U.S. Commercial Arm…

    Midatech Pharma Plc (MTP) is a biotechnology company with three novel drug delivery technologies that all improve bio-distribution and bio-delivery of drugs. The technologies achieve this via either the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs.

  • Who Are Midatech Pharma Plc’s (LON:MTPH) Major Shareholders?
    Simply Wall St.5 months ago

    Who Are Midatech Pharma Plc’s (LON:MTPH) Major Shareholders?

    If you want to know who really controls Midatech Pharma Plc (LON:MTPH), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock inRead More...

  • Zacks Small Cap Research5 months ago

    MTP: Positive Interim Results for MTD201 Proof-of-Concept Study…

    Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies that improve bio-distribution and bio-delivery of drugs. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.

  • Benzinga7 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Hasbro, Inc. (NASDAQ: HAS ) stock gained more than ...

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.

  • Zacks Small Cap Research10 months ago

    MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201

    Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.

  • Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry
    Simply Wall St.11 months ago

    Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry

    Examining how Münchener Tierpark Hellabrunn AG (MUN:MTP) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...

  • Zacks Small Cap Research11 months ago

    MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017

    On January 16, 2018, Midatech Pharma Plc (MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) application to initiate a clinical trial of MTX110 in patients with diffuse intrinsic pontine glioma (DIPG). The active compound in MTX110 is the poorly soluble hydroxamic acid drug panobinostat, a histone deacetylase inhibitor (HDACi), which until recently could not be formulated for parenteral administration.